The following leukodystrophy is characterized by the inability to properly catabolize very-long-chain fatty acids (VLCFA) within peroxisomes and with elevated levels of VLCFA in serum:
First, I need to recall the different types of leukodystrophies and their underlying metabolic issues. Leukodystrophies are disorders that affect the white matter of the brain, often due to problems in myelin production or maintenance. The question specifically mentions peroxisomes and VLCFA catabolism. Peroxisomes are involved in breaking down various molecules, including VLCFAs.
The most common leukodystrophy related to peroxisomal dysfunction is X-linked adrenoleukodystrophy (X-ALD). This condition is caused by mutations in the ABCD1 gene, which leads to the accumulation of VLCFAs because the peroxisomes can't break them down properly. Elevated VLCFA levels in the blood are a hallmark of this disease.
Now, looking at the options (even though they aren't listed here), the correct answer should be X-ALD. Other peroxisomal disorders might involve different substrates, like Zellweger syndrome, which affects peroxisome biogenesis generally and can lead to various metabolic issues, not specifically VLCFA. Another possibility could be Refsum disease, which is related to phytanic acid accumulation, but that's a different pathway.
So, the key points are the specific involvement of VLCFA catabolism and the peroxisomal defect. X-ALD fits this perfectly. The clinical pearl here is that elevated VLCFA in the serum is diagnostic for X-ALD, which is crucial for students to remember for exams.
**Core Concept**
This question tests knowledge of **peroxisomal disorders** and their associated metabolic defects. **X-linked adrenoleukodystrophy (X-ALD)** is a leukodystrophy caused by impaired **peroxisomal β-oxidation of very-long-chain fatty acids (VLCFA)**, leading to their toxic accumulation in serum and tissues.
**Why the Correct Answer is Right**
X-ALD is caused by mutations in the **ABCD1 gene**, encoding a peroxisomal transporter for VLCFAs. Defective transport prevents their catabolism via **peroxisomal β-oxidation**, resulting in **elevated serum VLCFA levels**. This disrupts **myelin sheath integrity** in the central nervous system and adrenal cortex, causing neurologic and endocrine manifestations. Diagnosis relies on **quantifying VLCFA levels** in plasma.
**Why Each Wrong Option is Incorrect**
**Option A:** **Zellweger syndrome** involves global peroxisomal dysfunction but presents with **multiple metabolic abnormalities** (e.g., elevated very-long-chain fatty acids, phytanic acid, pipecolic acid), not isolated VLCFA elevation.
**Option B:** **Refsum disease** is caused by **phytanic acid accumulation** due to **phytanoyl-CoA hydroxylase deficiency**, not VLCFA.
**Option C:** **Krabbe disease** is an **lysosomal storage disorder** (galactos